Podcast #58 CVR Medical Corp

Success for a tech company is ultimately a fairly straightforward equation: create some unique IP that satisfies some important need, and then find and develop large markets to commercialize the tech breakthrough. That is the formula being pursued by CVR Medical Corp. (TSX. V.CVM, OTCQB: CRRVF, Forum) (symbol “CVM”). Throw in a deep management team with decades of industry experience, and investors are presented with a very attractive opportunity.

Specifically, CVM has pioneered a highly innovative biotech device, to help to combat one of humanity’s most devastating medical problems: stroke. Globally, stroke is the single leading cause of permanent disability, with an equally devastating economic cost: $71.6 billion per year.

Stroke is also a deadly killer. Closer to home, stroke is the 4^th leading cause of death in the United States. Clearly, the need for better stroke-prevention technology is one of healthcare’s most important priorities.

CVR Medical’s “Carotid Stenotic Scan”, or CSS for short, is a major improvement from existing diagnostic technology. It is:

1. Non-invasive (no blood-draw is required)
2. Fast (only requiring roughly 2 minutes)
3. Repeatable (meaning it is totally safe for use)
4. Cost-effective versus existing diagnostics

CVR Medical has the right IP, that addresses an enormous medical need. What about markets? Last week, the Company announced a Letter of Intent (LOI) aimed at penetrating the largest healthcare market of them all: China. Stockhouse asked CVM’s COO and Executive Vice President, Tony Robinson, to help connect the dots for investors on the economic potential associated with this development.